|
Related Companies
|
[]
|
||||||||
|
Related Funds
|
[]
|
||||||||
|
|
|||||||||
|
English
|
|||||||||
|
oda_MaterialEventDisclosureGeneralAbstract|
|
|
||||||||
|
oda_UpdateAnnouncementFlag|
|
|
Evet (Yes)
|
|||||||
|
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
05.04.2024, 08.08.2024, 23.12.2024, 21.02.2025
|
|||||||
|
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_AnnouncementContentSection|
|
|
||||||||
|
oda_ExplanationSection|
|
|
||||||||
|
oda_ExplanationTextBlock|
|
In our disclosure dated 21.02.2025, it was stated that the Competition Board (Board) had conditionally approved the transfer of our 50% stake in the paid-in capital of Eczacıbaşı Monrol Nükleer Ürünler Sanayi ve Ticaret A.Ş., within the framework of the commitment letter submitted by the buyer, Curium International Trading B.V.
This time, we have been informed that the set of conditions specified in the commitment letter, that are subject to the approval of the Board, has been approved with the decision dated 20.03.2025.
This statement has been translated into English for informational purposes. In case of a discrepancy between the Turkish and the English versions of this disclosure statement, the Turkish version shall prevail.
|
||||||||